Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...